参苓白术颗粒联合奥替溴铵治疗肠易激综合征的临床研究  

Clinical study on Shenling Baizhu Granules combined with otionium bromide in treatment of irritable bowel syndrome

作　　者：安超 李淑悦 武海涛 邢路远 齐红松 AN Chao;LI Shu-yue;WU Hai-tao;XING Lu-yuan;QI Hong-song(Department of Gastroenterology,the Second Affiliated Hospital of Luohe Medical College,Luohe 462300,China;Department of Respiratory Medicine,The First Affiliated Hospital of Henan University,Kaifeng 450052,China)

机构地区：[1]漯河市医学高等专科学校第二附属医院消化内科,河南漯河462300 [2]河南大学第一附属医院呼吸内科,河南开封450052

出　　处：《现代药物与临床》2022年第8期1779-1783,共5页Drugs & Clinic

基　　金：开封市科技发展计划项目(1603083)。

摘　　要：目的探讨参苓白术颗粒联合奥替溴铵片治疗肠易激综合征的临床疗效。方法选择2020年3月—2021年11月漯河市医学高等专科学校第二附属医院消化内科收治的100例肠易激综合征患者,按随机数字表法将100例患者分为对照组和治疗组,每组各包括50例。对照组患者口服奥替溴铵片,1片/次,3次/d。治疗组在对照组基础上温水冲服参苓白术颗粒,1袋/次,3次/d。两组患者共治疗8周。观察两组的临床疗效,比较两组的症状消失时间、病情程度、血清过氧化还原酶1(PRDX1)、白细胞介素-13(IL-13)、肿瘤坏死因子-α(TNF-α)水平。结果治疗后,治疗组的总有效率为94.00%,对照组的总有效率为78.00%,组间比较差异显著(P<0.05)。治疗后,治疗组患者腹痛、腹泻、腹胀消失时间均短于对照组(P<0.05)。治疗后,两组的肠易激综合征症状严重度量表(IBS-SSS)腹痛程度、排便满意度、腹部不适、腹痛频次、生活影响评分均低于治疗前(P<0.05),且治疗组的IBS-SSS各项评分均明显低于对照组(P<0.05)。治疗后,两组的血清IL-13水平高于治疗前,血清PRDX1、TNF-α水平低于治疗前(P<0.05);治疗组的血清IL-13水平高于对照组,血清PRDX1、TNF-α水平低于对照组(P<0.05)。结论参苓白术颗粒联合奥替溴铵片治疗肠易激综合征的疗效确切,能控制病情程度,减轻炎症反应,并且安全性良好。Objective To investigate the clinical efficacy of Shenling Baizhu Granules combined with Otionium Bromide Tablets in treatment of irritable bowel syndrome.Methods Patients(100 cases)with irritable bowel syndrome in the Second Affiliated Hospital of Luohe Medical College from March 2020 to November 2021 were randomly divided into control and treatment groups,and each group had 50 cases.Patients in the control group were po administered with Otionium Bromide Tablets,1 tablet/time,three times daily.Patients in the treatment group were po administered with Shenling Baizhu Granules on the basis of the control group,1 bag/time,three times daily.Patients in two groups were treated for 8 weeks.After treatment,the clinical efficacies were evaluated,and the disappearance time of symptom,the degree of illness,and the serum levels of PRDX1,IL-13,and TNF-αin two groups were compared.Results After treatment,the total effective rate of the treatment group was 94.00%,that of the control group was 78.00%,,and there was significant difference between the groups(P<0.05).After treatment,the disappearance time of abdominal pain,diarrhea,and abdominal distension in the treatment group was lower than that in the control group(P<0.05).After treatment,the scores of abdominal pain,defecation satisfaction,abdominal discomfort,abdominal pain frequency,and life impact of IBS-SSS in two groups were lower than those before treatment(P<0.05),and the scores of abdominal pain,defecation satisfaction,abdominal discomfort,abdominal pain frequency,and life impact of IBS-SSS in the treatment group were significantly lower than those in the control group(P<0.05).After treatment,the serum levels of IL-13 in two groups were higher than those before treatment,but the serum levels of PRDX1 and TNF-αwere lower than those before treatment(P<0.05).The levels of serum IL-13 in the treatment group were higher than those in the control group,but the serum levels of PRDX1 and TNF-αwere lower than those in the control group(P<0.05).Conclusion Shenling Baizhu G

关 键 词：参苓白术颗粒 奥替溴铵片 肠易激综合征 腹痛消失时间 肠易激综合征症状严重度量表评分 过氧化物酶1 白细胞介素-13 肿瘤坏死因子-α 

分 类 号：R975[医药卫生—药品]